List view / Grid view
Three-dimensional cell cultures (spheroids, organoids) are becoming widely used as a new predictive tool in early drug discovery. The use of 3D cell cultures is believed to provide a more physiologically relevant response than monolayer (2D) cell cultures because they closely mimic the extracellular matrix and cell-cell interactions that occur…
The basic premise of drug discovery screening necessitates that the biological assays upon which it depends can be performed in a reproducible manner. In addition, the techniques employed must generate results that are biologically relevant and actionable.
The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.
For drug discovery and biomarker research, screening campaigns are employed to identify potential new treatments for diseases and to answer questions that remain unknown in the scientific community.
High-throughput screening (HTS) technologies have enabled the routine testing of millions of compounds towards the identification of novel ‘hit’ molecules for therapeutic targets. Oftentimes in this drug discovery process, however, compounds that show promising activity in primary screens show no activity during subsequent hit qualification or progression efforts.
Researchers are always looking more effective and efficient ways of making their work more successful. In this supplement, some of our commercial partners share their data, detailing the application of their technology.
Data integrity and computerised system validations (CSV) have become an area of increased scrutiny for regulatory agencies over the last several years. Understanding how the agencies view data integrity is critical for laboratories to maintain complete compliance.
Earlier this year, the National Cancer Institute published its annual report to the nation on the status of cancer stating that there will be nearly 1.8 million new cases of cancer in 2018.1 New therapies have developed over time to improve cancer patient outcomes, including antibody immunotherapies targeting immune checkpoints,…
Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.
Contract Research Organisations rely on microplate readers for effective hit discovery. Ian Waddell, of Charles River Laboratories, explains what his needs are.
This In-Depth Focus examines our understanding of the comprehensive and complex innate immune system, to develop novel treatments and an open source model to eliminate nuisance compounds
This In-Depth Focus looks at a high-throughput approach for measuring intracellular ATP levels to access compound-mediated cellular toxicity, the role of drug transporters in phenotypic screening, and how to leverage the power of HTS in the new and rapidly evolving collaborative drug discovery landscape.
In this supplement: Omics-informed drug target discovery in combating emerging infectious diseases, and self-delivering RNAi: paving the way for a new class of cancer immunotherapies.
Despite being one of the more ancient aspects of immunity, therapeutic modulation of the innate immune system has rarely been attempted. Innate immunity is intrinsically linked to the generation of inflammation – necessary for signalling to the adaptive immune system but often self-perpetuating and over-exaggerated, leading to deleterious effects, including…
Over the last five years drug discovery has undergone a rapid evolution from a closed and proprietary endeavour to an open and collaborative process. Large and small pharma now openly collaborate with each other and the wider academic world to leverage their collective depth of knowledge to increase the chances…
